News Column

Definiens Enters into Pact with Clarient

February 15, 2014

Definiens, a company focused on image analysis for digital pathology and diagnostics, announced the signing of an agreement with Clarient Diagnostic Services, which extends the use of Definiens' automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer.

According to a release, Definiens' proprietary Cognition Network Technology is core to automatically classify and quantitate key tissue features as part of Clarient's Scope IA Platform offering to its pathology customers.

"At Clarient, we combine world class pathology with innovation and our goal is to make a difference to physicians and their patients," said Kenneth Bloom, MD, Chief Medical Officer, Clarient Diagnostic Services, Inc. "Our work with Definiens will enable us to offer high quality, robust readouts with fast turnaround time. This means physicians will have better patient insights for diagnosis."

"We are really pleased to work with Clarient on creating these validated applications for their routine clinical work. Running thousands of patient slides through our algorithms and seeing the computer-aided diagnosis in action is really gratifying," said Thomas Heydler, CEO of Definiens. "No one else has done this on such a large scale."

Definiens noted its Cognition Network Technology was invented by 1986 Nobel prize winner Gerd Binnig and is unique in its ability to extract information from tissue images, a process known as tissue datafication. Definiens applies the technology for solutions in discovery, preclinical, and diagnostic imaging.

More Information:

www.definiens.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Professional Services Close - Up


Story Tools